首页> 外文期刊>Journal of Medicinal Chemistry >Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents.
【24h】

Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents.

机译:合成的2-aroylindole衍生物是一类新型的抑制微管蛋白的强效抗有丝分裂剂。

获取原文
获取原文并翻译 | 示例
           

摘要

A new class of simple synthetic antimitotic compounds based on 2-aroylindoles was discovered. (5-Methoxy-1H-2-indolyl)-phenylmethanone (1) as well as analogous 3-fluorophenyl- (36) and 3-methoxyphenyl (3) derivatives displayed high cytotoxicity of IC(50) = 20 to 75 nM against the human HeLa/KB cervical, SK-OV-3 ovarian, and U373 astrocytoma carcinoma cell lines. The inhibition of proliferation correlated with the arrest in the G2/M phase of the cell cycle. In in vitro assays with tubulin isolated from bovine brain, in general antiproliferative activity correlated with inhibition of tubulin polymerization. Thus, the antimitotic activity of 2-aroylindoles is explained by interference with the mitotic spindle apparatus and destabilization of microtubules. In contrast to colchicine, vincristine, nocodazole, or taxol, 1 did not significantly affect the GTPase activity of beta-tubulin. Interestingly, selected compounds inhibited angiogenesis in the chorioallantoic membrane (CAM) assay. In xenograft experiments, 1 was highly active after oral administration at 200 mg/kg against the human amelanocytic melanoma MEXF 989 in athymic nude mice. We conclude, that 2-aroylindoles constitute an interesting new class of antitubulin agents with the potential to be clinically developed for cancer treatment.
机译:发现了一类新的基于2-芳基吲哚的简单的合成抗有丝分裂化合物。 (5-甲氧基-1H-2-吲哚基)-苯基甲酮(1)以及类似的3-氟苯基-(36)和3-甲氧基苯基(3)衍生物显示出高的IC(50)细胞毒性,对IC的毒性为20至75 nM。人HeLa / KB宫颈癌,SK-OV-3卵巢癌和U373星形细胞瘤癌细胞系。增殖的抑制与细胞周期的G2 / M期停滞有关。在从牛脑分离的微管蛋白的体外测定中,一般而言,抗增殖活性与微管蛋白聚合的抑制有关。因此,通过干扰有丝分裂纺锤体设备和微管的不稳定来解释2-芳基吲哚的抗有丝分裂活性。与秋水仙碱,长春新碱,诺考达唑或紫杉醇相反,1不会显着影响β-微管蛋白的GTPase活性。有趣的是,选定的化合物在绒膜尿囊膜(CAM)分析中抑制了血管生成。在异种移植实验中,在无胸腺裸鼠中以200 mg / kg口服给药后,有1种抗人成釉细胞黑色素瘤MEXF 989具有很高的活性。我们得出的结论是,2-芳基吲哚构成了有趣的一类新的抗微管蛋白药物,具有临床开发用于癌症治疗的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号